REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
Claude calling Anthropic's S-1 insightful is zero surprise. Like it was ever going to call its own maker's filing boring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results